ST. JOSEPH, Mich., Sept. 8 /PRNewswire/ -- GeneGo, Inc., the leading systems
biology tools company, announced today that Proteostasis Therapeutics has
licensed its data mining and analysis platform, MetaCore. Proteostasis
Therapeutics is the first company dedicated to the discovery of novel small
molecule therapeutics based upon understanding the body's Proteostasis
Network. The Proteostasis Network maintains the body's natural balance of
proteins to protect us from numerous diseases. Deficiencies of the
Proteostasis Network can lead to a wide spectrum of diseases, such as
emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
GeneGo's MetaCore is developing pathway reconstruction maps for a number of
disease categories, including neurodegenerative disorders. Disease-specific
pathway maps and models can be used as analytical tools to help advance our
understanding of the diseases, their mechanisms and processes to help find
cures faster.
